In accordance with the theragnostic concept, 68Ga-PSMA-11 PET/CT can be used to assess response to therapy with 177Lu-/225Ac-PSMA-617 in patients with metastatic castration–resistant PC (mCRPC). The gene discussed is FOLH1; the disease is pachyonychia congenita.